ยินดีต้อนรับกลับมา
เข้าร่วม CoinTime
เข้าสู่ระบบ email
สร้างบัญชี email
ตรวจสอบกล่องจดหมายของคุณ
Metcela
About
Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- ¥1.87B
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Mar 9, 2016
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies. Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure.It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 28, 2022 | Series C | ¥1.87B | 1 |
|
— | Detail |
| Jan 4, 2021 | Series B | $12.70M | 1 | — | — | Detail |
| Mar 18, 2020 | Series B | ¥430M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series C |
|
|
— | Series B |
